Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort

BACKGROUND: Apalutamide is a potent androgen receptor (AR) antagonist that targets the AR ligand-binding domain and prevents AR nuclear translocation, DNA binding, and transcription of AR gene targets. Objective: To evaluate the activity and safety of apalutamide in patients with high-risk nonmetast...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Matthew R., Antonarakis, Emmanuel S., Ryan, Charles J., Berry, William R., Shore, Neal D., Liu, Glenn, Alumkal, Joshi J., Higano, Celestia S., Maneval, Edna Chow, Bandekar, Rajesh, de Boer, Carla J., Yu, Margaret K., Rathkopf, Dana E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568792/
https://www.ncbi.nlm.nih.gov/pubmed/27160947
http://dx.doi.org/10.1016/j.eururo.2016.04.023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568792/
https://www.ncbi.nlm.nih.gov/pubmed/27160947
http://dx.doi.org/10.1016/j.eururo.2016.04.023

Ejemplares similares